Celera and GenData in autoimmune disease pact:
This article was originally published in Clinica
US firms Celera Diagnostics and GenData Research have teamed up in a project to identify genetic markers associated with an autoimmune disease. GenData, a commercial contract research and licensing partner of the University of Utah, in Salt Lake City, will provide DNA samples and associated clinical information to support Celera's marker discovery research. Last month, GenData formed a deal with Columbus, Ohio firm Battelle to discover, develop and commercialise biomarkers for diagnostic and therapeutic applications in chronic obstructive pulmonary disease.
You may also be interested in...
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.